Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POL7080 plus standard of care for ventilator-associated pneumonia due to suspected or documented Pseudomonas aeruginosa
2013-001596-21Phase 2Terminated
- Sponsor
- Polyphor
- Start
- Jun 2013
- Modality
- Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of murepavadin in ventilator-associated pneumonia (VAP) and Pseudomonal infection, sponsored by Polyphor. Primary endpoint: Pharmacokinetic characteristics of POL7080. Started Jun 2013; status: terminated.
02
Drugs
murepavadin
03
Conditions
ventilator-associated pneumonia (VAP)Pseudomonal infection
Beyond the preview
Go deeper on 2013-001596-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001596-21.